Three dose levels of a maternal respiratory syncytial virus vaccine candidate are well tolerated and immunogenic in a randomized trial in nonpregnant women

HIGHLIGHTS

• who: Respiratory syncytial virus (RSV) and collaborators from the Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany, Johnson County Clin-Trials, Lenexa, Kansas, USA, Clinical Research Hamburg, Hamburg, Germany, VL-Medi, Helsinki, Finland, Centre for Child Health Research, Tampere University, Tampere, Finland, Terveystalo Turku Vaccine Clinic, Turku, Finland, GSK, Wavre, Belgium, GSK, Rockville, Maryland, USA, and GSK, Rixensart, Belgium have published the research: Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women, in the Journal . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.